Welcome to LookChem.com Sign In|Join Free


  • or


Post Buying Request

41443-28-1 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

41443-28-1 Usage


ODQ (41443-28-1) is a potent and selective inhibitor of soluble guanylyl cyclase (sGC),?IC50?= 20 nM).1 ODQ acts via competition with NO for the heme site of sGC where it binds irreversibly.2?ODQ does not inhibit NO-mediated macrophage toxicity, an activity that is unrelated to cGMP nor does it inhibit particulate GC.1?ODQ is an extremely useful tool to explore the involvement of the NO-cGMP pathway in cellular signaling and physiologic processes.3-5

Chemical Properties

ODQ is off-white to yellow powder


Different sources of media describe the Uses of 41443-28-1 differently. You can refer to the following data:
1. ODQ is a selective and potent sGC (soluble guanylyl cyclase) inhibitor.
2. 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one inhibits neurite outgrowth and causes neurite retraction in PC12 cells independently of soluble guanylyl cyclase.

Biological Activity

ODQ is a potent and selective inhibitor of NO-sensitive guanylyl cyclase.

Biochem/physiol Actions

H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) non competitively inhibits the action of nitric oxide-sensitive guanylyl cyclase and results in a supposedly irreversible oxidation of the prosthetic heme group. ODQ has been used to study the role of cyclic guanosine monophosphate (cGMP) pathway in nitric oxide (NO) signal transduction.


1) Garthwaite?et al.?(1995),?Potent and Selective Inhibition of Nitric Oxide-sensitive Guanylyl Cyclase by 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one; Mol. Pharmacol.?48?184 2) Schrammel?et al.?(1996),?Characterization of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase; Mol. Pharmacol.?50?1 3) Estevez?et al.?(1998),?Nitric oxide-dependent production of cGMP supports the survival of rat embryonic motor neurons cultured with brain-derived neurotrophic factor; J. Neurosci.?18?3708 4) Vandecasteele?et al.?(1998),?Role of the NO-cGMP in the muscarinic regulation of the L-type Ca2+ current in human atrial myocytes; J. Physiol.?506?653 5) Martins-Pinge?et al.?(1999),?Nitric oxide-dependent guanylyl cyclase participates in the glutamatergic neurotransmission within the rostral ventrolateral medulla of awake rats;?Hypertension?34?748

Check Digit Verification of cas no

The CAS Registry Mumber 41443-28-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 4,1,4,4 and 3 respectively; the second part has 2 digits, 2 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 41443-28:
91 % 10 = 1
So 41443-28-1 is a valid CAS Registry Number.

41443-28-1 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • TCI America

  • (O0400)  1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one  >95.0%(GC)

  • 41443-28-1

  • 25mg

  • 2,150.00CNY

  • Detail



According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 11, 2017

Revision Date: Aug 11, 2017


1.1 GHS Product identifier

Product name [1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one

1.2 Other means of identification

Product number -
Other names Lopac-O-3636

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:41443-28-1 SDS

41443-28-1Downstream Products

41443-28-1Relevant articles and documents

Suzuki-Miyaura reactions of the soluble guanylate cyclase inhibitor NS2028: A non-product specific route to C-8 substituted analogues

Berezin, Andrey A.,Koutentis, Panayiotis A.

, p. 4069 - 4078 (2011/06/24)

Both soluble guanylate cyclase (sGC) inhibitors ODQ 1 and NS2028 2 are synthesized via improved protocols. In the former case treating 3,4-dihydroquinoxalin-2(1H)-one oxime 8, which can be prepared in two steps from 1,2-benzenediamine, with 1,1′-carbonyldiimidazole (CDI) gives the dihydro-ODQ 10 that in the presence of KMnO4 oxidises to give ODQ 1 in an overall yield of 46% starting from 1,2-benzenediamine. In the latter case, the synthesis affords NS2028 2 from 2-amino-4-bromophenol 3 in three steps with an overall yield of 85% and avoids the need for chromatography. Furthermore, Suzuki-Miyaura reaction conditions are described that enable the preparation of 8-aryl and 8-heteroaryl derivatives of NS2028 directly from NS2028 2. Finally, demethylation of the 8-(methoxyphenyl) substituted analogues afforded the 8-(hydroxyphenyl) derivatives 40-42. All new products are fully characterised.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)


What can I do for you?
Get Best Price

Get Best Price for 41443-28-1